Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Farrukh Ansari

Interventional Pain Medicine Albany, NY Medical Doctor

NPI 1174814933 CMS profile 453883

121 Everett Rd, Albany, NY 12205

Open in the dashboard

General payments

$5,699

130 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Farrukh Ansari of Albany, NY is reported in the CMS Open Payments database as having received $5,699 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $505 15
2024 General $606 27
2023 General $2,292 24
2022 General $518 19
2021 General $468 18
2020 General $414 7
2019 General $897 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Farrukh Ansari
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Farrukh Ansari were reported at $505. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Farrukh Ansari Interventional Pain Medicine median Middle half National median
2019 $897 $684 $216–$2,079 $163
2020 $414 $382 $122–$1,109 $114
2021 $468 $552 $167–$1,554 $132
2022 $518 $605 $187–$1,924 $149
2023 $2,292 $671 $195–$1,915 $160
2024 $606 $684 $206–$1,837 $164
2025 $505 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Prodigy Surgical Distribution, Inc. $1,472 3 payments
  2. Boston Scientific Corporation $1,115 32 payments
  3. Nevro Corp. $1,094 28 payments
  4. Abbott Laboratories $676 26 payments
  5. Saluda Medical Americas, Inc. $287 4 payments
  6. Arthrex, Inc. $270 3 payments
  7. Allergan Inc. $176 7 payments
  8. Globus Medical, Inc. $111 5 payments
  9. International Rehabilitative Sciences, Inc $100 3 payments
  10. Vertex Pharmaceuticals Incorporated $76 4 payments
  11. Other $322 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,358 128 payments
  2. Travel and Lodging $1,342 2 payments
Products named General payments · program years 2019–2025
  1. Senza Spinal Cord Stimulation System $608 7 payments
  2. Proclaim Family of SCS IPGs $301 6 payments
  3. Omnia $292 9 payments
  4. WaveWriter Alpha Prime 16 $261 11 payments
  5. PROCLAIM $210 11 payments
  6. Senza $194 12 payments
  7. Evoke $190 3 payments
  8. BOTOX $176 7 payments
  9. Superion Indirect Decompression System $137 1 payment
  10. SPECTRA WAVEWRITER $124 1 payment
  11. Other $1,096 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$163,644

Of which drugs: $3,514

Medicare patients

457

Average age 74

Services billed

6,760

280 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 34%
Depression 26%
Diabetes 24%
Osteoporosis 18%
Chronic kidney disease 17%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 99 474 $2,592
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 113 669 $510
Injection, methylprednisolone acetate, 1 mg J1010 Office 42 3,360 $328
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 58 615 $55

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record